Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Other 1Gynecologic 1

Conditions

Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 281Specimen Handling 271pembrolizumab 253Cyclophosphamide 235Radiotherapy 227Nivolumab 184Cisplatin 172Biopsy 161Carboplatin 155Radiosurgery 143fludarabine 131Blood Specimen Collection 129Surveys and Questionnaires 120Gemcitabine 119Paclitaxel 116venetoclax 114Standard of Care 112Dexamethasone 107Bevacizumab 93Radiation 92Rituximab 91Oxaliplatin 89Cytarabine 88Ipilimumab 84Drug Therapy 84Capecitabine 84Doxorubicin 81durvalumab 80fludarabine phosphate 73Fluorouracil 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Bupropion × 90 days × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡